Market Overview

KYTHERA Biopharmaceuticals Announces Positive Interim Phase IIIb Results from Open-Label Study of ATX-101

KYTHERA Biopharmaceuticals (NASDAQ: KYTH) today announced positive
interim results from a Phase IIIb, multicenter, open-label study
(ATX-101-11-26) of ATX-101 during the “Innovations and Renewals” session
of the 11th Anti-Aging Medicine World Congress (AMWC), April
4-6, Monte Carlo, Monaco. The study, presented by investigator Susan
Weinkle, MD, FAAD, evaluated the safety and efficacy of ATX-101, a
potential first-in-class, non-surgical, injectable drug in Phase III
trials for the reduction of unwanted submental fat (SMF), commonly known
as “double chin.” The results found that ATX-101 is well tolerated and
may be effective in reducing SMF by both clinician- and patient-reported
outcome measures. AMWC is the world's largest event for global aging
management, and attracts aesthetic dermatologists, surgeons and

See full press release

Posted-In: News Guidance Asset Sales Management

 

Related Articles (KYTH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters